Unnamed: 0,title,date,stock,sentiment
254519.0,34 Stocks Moving in Wednesday's Pre-Market Session,2020-06-10 07:17:00-04:00,CLRB,neutral
254520.0,"Aigh Capital Management, Llc. Reports A Passive Stake Of 6.52% In Cellectar Biosciences As Of June 3",2020-06-10 06:38:00-04:00,CLRB,positive
254521.0,"The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic",2020-06-04 08:13:00-04:00,CLRB,positive
254522.0,85 Biggest Movers From Yesterday,2020-06-04 05:02:00-04:00,CLRB,neutral
254523.0,58 Stocks Moving In Wednesday's Mid-Day Session,2020-06-03 12:18:00-04:00,CLRB,neutral
254524.0,Stocks That Hit 52-Week Lows On Wednesday,2020-06-03 11:21:00-04:00,CLRB,negative
254525.0,Cellectar Biosciences Announces Pricing of $20 Million Underwritten Public Offering At $1.15 Per Share,2020-06-03 09:02:00-04:00,CLRB,positive
254526.0,31 Stocks Moving in Wednesday's Pre-Market Session,2020-06-03 07:10:00-04:00,CLRB,neutral
254527.0,Cellectar Granted SME Status By European Medicines Agency,2020-06-01 08:14:00-04:00,CLRB,positive
254528.0,70 Biggest Movers From Yesterday,2020-05-28 06:09:00-04:00,CLRB,neutral
254529.0,58 Stocks Moving In Wednesday's Mid-Day Session,2020-05-27 12:19:00-04:00,CLRB,neutral
254530.0,33 Stocks Moving in Wednesday's Pre-Market Session,2020-05-27 07:19:00-04:00,CLRB,neutral
254531.0,96 Biggest Movers From Yesterday,2020-05-27 04:20:00-04:00,CLRB,neutral
254532.0,61 Stocks Moving In Tuesday's Mid-Day Session,2020-05-26 12:29:00-04:00,CLRB,neutral
254533.0,P/E Ratio Insights for Cellectar Biosciences,2020-05-26 11:10:00-04:00,CLRB,neutral
254534.0,Cellectar Biosciences shares are trading higher after the company reported it received FDA fast track designation for CLR 131 in Lymphoplasmacytic Lymphoma and Waldenstrom's Macroglobulinemia.,2020-05-26 08:46:00-04:00,CLRB,positive
254535.0,Cellectar Receives FDA Fast Track Designation For CLR 131 In Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinemia,2020-05-26 07:47:00-04:00,CLRB,neutral
254536.0,Cellectar Granted Composition Of Matter And Use Patent In Europe For CLR 131,2020-05-14 08:31:00-04:00,CLRB,positive
254537.0,Cellectar Biosciences Q1 EPS $(0.420) Up From $(0.760) YoY,2020-05-07 08:45:00-04:00,CLRB,neutral
254538.0,Shares of several energy companies are trading higher amid hopes of output cuts by major oil producers Russia and Saudi Arabia to support prices.,2020-04-08 09:52:00-04:00,CLRB,positive
254539.0,Cellectar Biosciences Q4 EPS $(0.33) Down From $0.06 YoY,2020-03-09 08:03:00-04:00,CLRB,neutral
254540.0,95 Biggest Movers From Yesterday,2020-02-21 05:12:00-05:00,CLRB,neutral
254541.0,71 Stocks Moving In Thursday's Mid-Day Session,2020-02-20 12:16:00-05:00,CLRB,neutral
254542.0,78 Biggest Movers From Yesterday,2020-02-20 05:16:00-05:00,CLRB,neutral
254543.0,25 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-02-19 08:10:00-05:00,CLRB,neutral
254544.0,"The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA",2020-02-19 07:21:00-05:00,CLRB,negative
254545.0,35 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-02-18 08:25:00-05:00,CLRB,neutral
254546.0,"The Week Ahead In Biotech: Baudax Bio, Merck, Esperion Await FDA Decisions",2020-02-16 15:03:00-05:00,CLRB,positive
254547.0,"Roth Capital Assumes Cellectar Biosciences at Buy, Announces $10 Price Target",2020-01-21 09:05:00-05:00,CLRB,neutral
254548.0,58 Biggest Movers From Friday,2019-12-30 04:51:00-05:00,CLRB,neutral
254549.0,60 Biggest Movers From Yesterday,2019-12-27 04:44:00-05:00,CLRB,neutral
254550.0,Cellectar Biosciences Receives FDA Orphan Drug Designation For 18-(p-[131I]-iodophenyl)octadecyl phosphocholine,2019-12-23 15:03:00-05:00,CLRB,neutral
254551.0,Cellectar Biosciences Announces a 30% Overall Response Rate in Patients Receiving a Single Dose of CLR 131 in the Phase 2 CLOVER-1 Study,2019-12-16 08:05:00-05:00,CLRB,neutral
254552.0,Cellectar Biosciences Announces Presentation Of Fractionated Dosing Data Of CLR 131 In Relapsed Or Refractory Multiple Myeloma Patients,2019-12-09 08:34:00-05:00,CLRB,neutral
254553.0,"The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval",2019-11-15 07:08:00-05:00,CLRB,negative
254554.0,"The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher",2019-11-13 07:10:00-05:00,CLRB,neutral
254555.0,Cellectar Biosciences Q3 EPS $(0.42) Up From $(1.65) YoY,2019-11-12 09:07:00-05:00,CLRB,neutral
254556.0,Cellectar Highlights Presentation Of New Phospholipid Drug Conjugate At AACR-NCI-EORTC Conference,2019-10-30 08:13:00-04:00,CLRB,neutral
254557.0,Cellectar Presents Data From DLBCL Cohort Of Phase 2 CLOVER-1 Study at At European Society For Medical Oncology Congress,2019-09-30 08:33:00-04:00,CLRB,neutral
254558.0,23 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-09-25 08:17:00-04:00,CLRB,neutral
254559.0,Cellectar Receives Orphan Drug Designation From The European Commission For CLR 131 In Multiple Myeloma,2019-09-24 08:04:00-04:00,CLRB,neutral
254560.0,35 Stocks Moving In Friday's Mid-Day Session,2019-09-13 12:56:00-04:00,CLRB,neutral
254561.0,"Roth Capital Initiates Coverage On Cellectar Biosciences with Buy Rating, Announces $11 Price Target",2019-09-13 09:11:00-04:00,CLRB,neutral
254562.0,"The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight",2019-09-08 11:01:00-04:00,CLRB,neutral
254563.0,Cellectar Biosciences Names Dov Elefant CFO,2019-08-15 08:40:00-04:00,CLRB,neutral
254564.0,Cellectar Biosciences Q2 EPS $(0.46) Beats $(0.69) Estimate,2019-08-12 08:05:00-04:00,CLRB,neutral
254565.0,50 Healthcare Stocks Moving In Thursday's After-Market Session,2019-08-08 21:56:00-04:00,CLRB,neutral
254566.0,"Benzinga's Top Upgrades, Downgrades For July 30, 2019",2019-07-30 09:59:00-04:00,CLRB,positive
254567.0,42 Stocks Moving In Tuesday's Pre-Market Session,2019-07-30 08:14:00-04:00,CLRB,neutral
254568.0,"Brookline Capital Initiates Coverage On Cellectar Biosciences with Buy Rating, Announces $6 Price Target",2019-07-30 06:44:00-04:00,CLRB,neutral
254569.0,45 Healthcare Stocks Moving In Monday's After-Market Session,2019-07-30 04:54:00-04:00,CLRB,neutral
254570.0,Cellectar Biosciences shares are trading higher after the company received FDA fast track designation for CLR 131 in diffuse large B-Cell Lymphoma.,2019-07-09 08:36:00-04:00,CLRB,positive
254571.0,Cellectar Receives FDA Fast Track Designation For CLR 131 In Diffuse Large B-Cell Lymphoma,2019-07-09 08:32:00-04:00,CLRB,neutral
254572.0,50 Biggest Movers From Yesterday,2019-06-13 05:44:00-04:00,CLRB,neutral
254573.0,35 Stocks Moving In Wednesday's Mid-Day Session,2019-06-12 12:54:00-04:00,CLRB,neutral
254574.0,Shares of several oil and gas companies are trading lower following negative oil price catalysts. EIA on Wednesday cut 2019 demand forecasts while there was a reported increase in crude inventories. US-China trade tensions have weighed on demand outlook.,2019-06-12 10:07:00-04:00,CLRB,negative
254575.0,"The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache",2019-06-05 07:30:00-04:00,CLRB,positive
254576.0,28 Stocks Moving In Wednesday's Pre-Market Session,2019-05-29 08:16:00-04:00,CLRB,neutral
254577.0,Cellectar Biosciences shares are trading higher after the company reported expansion of third cohort of phase 2 CLOVER-1 study of CLR 131.,2019-05-21 08:57:00-04:00,CLRB,positive
254578.0,Cellectar Biosciences Reports Expansion Of Third Cohort Of Phase 2 CLOVER-1 Study Of CLR 131,2019-05-21 08:35:00-04:00,CLRB,neutral
254579.0,60 Biggest Movers From Friday,2019-05-20 05:06:00-04:00,CLRB,neutral
254580.0,44 Stocks Moving In Friday's Mid-Day Session,2019-05-17 12:26:00-04:00,CLRB,neutral
254581.0,22 Stocks Moving In Friday's Pre-Market Session,2019-05-17 08:01:00-04:00,CLRB,neutral
254582.0,63 Biggest Movers From Yesterday,2019-05-17 05:05:00-04:00,CLRB,neutral
254583.0,"A Look At Benzinga Pro's 10 Most-Searched Tickers For May 16, 2019",2019-05-16 16:52:00-04:00,CLRB,neutral
254584.0,Mid-Afternoon Market Update: KEMET Jumps On Upbeat Q4 Results; EDAP Shares Plunge,2019-05-16 14:38:00-04:00,CLRB,positive
254585.0,50 Stocks Moving In Thursday's Mid-Day Session,2019-05-16 12:36:00-04:00,CLRB,neutral
254586.0,Mid-Day Market Update: Crude Oil Up Over 2%; Virtusa Shares Drop Following Downbeat Q4 Earnings,2019-05-16 12:18:00-04:00,CLRB,negative
254587.0,Mid-Morning Market Update: Markets Open Higher; Walmart Earnings Top Expectations,2019-05-16 10:12:00-04:00,CLRB,positive
254588.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Thur., May 16, 2019",2019-05-16 10:00:00-04:00,CLRB,positive
254589.0,"Cellectar Biosciences Reports $10M Financing: $5M In Registered Direct Offering Of ~1.982M Common Shares, $5M Concurrent Private Placement Of 2.018M Common Shares",2019-05-16 08:55:00-04:00,CLRB,positive
254590.0,30 Stocks Moving In Thursday's Pre-Market Session,2019-05-16 08:12:00-04:00,CLRB,neutral
254591.0,60 Biggest Movers From Yesterday,2019-05-16 05:12:00-04:00,CLRB,neutral
254592.0,44 Stocks Moving In Wednesday's Mid-Day Session,2019-05-15 12:56:00-04:00,CLRB,neutral
254593.0,Mid-Morning Market Update: Markets Mostly Lower; Macy's Earnings Top Estimates,2019-05-15 10:19:00-04:00,CLRB,negative
254594.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tue., May 14, 2019",2019-05-14 10:35:00-04:00,CLRB,positive
254595.0,42 Stocks Moving In Monday's Mid-Day Session,2019-05-13 12:48:00-04:00,CLRB,neutral
254596.0,"Benzinga Pro's Top 8 Most-Searched Tickers For Morning of Mon., May 13, 2019",2019-05-13 10:24:00-04:00,CLRB,positive
254597.0,Cellectar Recieves FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma,2019-05-13 08:09:00-04:00,CLRB,neutral
254598.0,"Shares of several oil companies are trading lower as oil prices fall. US-China trade concerns have caused concern over global oil demand outlook, outweighing the positive effect of falling US crude stockpiles.",2019-05-09 10:44:00-04:00,CLRB,negative
254599.0,Cellectar Biosciences Q1 EPS $(0.76) Misses $(0.74) Estimate,2019-05-06 08:05:00-04:00,CLRB,negative
254600.0,5 Biotech Stocks With Near-Term Catalysts Ahead,2019-05-02 14:18:00-04:00,CLRB,neutral
254601.0,"H.C. Wainwright Initiates Coverage On Cellectar Biosciences, Inc. - Common Stock with Buy Rating, Announces $4 Price Target",2019-05-02 09:45:00-04:00,CLRB,neutral
254602.0,Shares of several oil companies are trading higher following a 2% climb in the price of crude oil due to investor sentiment that OPEC supply cuts and lower US inventory have outweighed concern for weaker demand.,2019-03-26 09:55:00-04:00,CLRB,negative
254603.0,52 Biggest Movers From Yesterday,2019-03-21 04:59:00-04:00,CLRB,neutral
254604.0,41 Stocks Moving In Wednesday's Mid-Day Session,2019-03-20 12:00:00-04:00,CLRB,neutral
254605.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Wed., Mar. 20, 2019",2019-03-20 09:36:00-04:00,CLRB,positive
254606.0,45 Stocks Moving In Tuesday's Mid-Day Session,2019-03-19 13:21:00-04:00,CLRB,neutral
254607.0,45 Stocks Moving In Tuesday's Mid-Day Session,2019-03-19 13:10:00-04:00,CLRB,neutral
254608.0,Cellectar Biosciences shares are trading higher after the FDA granted an exemption to the import alert for Cellectar's CLR 131 in pediatric and adolescent patients,2019-03-19 09:26:00-04:00,CLRB,positive
254609.0,FDA Grants Exemption To Import Alert For Cellectar's CLR 131 In Pediatric And Adolescent Patients,2019-03-19 08:32:00-04:00,CLRB,positive
254610.0,60 Biggest Movers From Yesterday,2019-03-19 05:24:00-04:00,CLRB,neutral
254611.0,64 Biggest Movers From Yesterday,2019-03-08 05:22:00-05:00,CLRB,neutral
254612.0,51 Stocks Moving In Thursday's Mid-Day Session,2019-03-07 12:32:00-05:00,CLRB,neutral
254613.0,"Cellectar Shares Sharply Higher, Not Seeing Fundamental News; Co. Is Likely A Low-Float Play, Has 1.7M Shares In Float; Unknown Twitter Source Suggests Stock Is 'next direct sympathy of Bio-Path'; Benzinga Has Not Confirmed This Information",2019-03-07 11:09:00-05:00,CLRB,positive
254614.0,"Cellectar Biosciences Shares Spike To Session High, Now Up 15%",2019-03-07 11:03:00-05:00,CLRB,positive
254615.0,"The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings",2019-03-05 07:24:00-05:00,CLRB,positive
254616.0,54 Stocks Moving In Tuesday's Mid-Day Session,2019-02-26 12:18:00-05:00,CLRB,neutral
254617.0,Cellectar FY18 EPS $(5.23) vs $(10.70) In FY17,2019-02-26 08:48:00-05:00,CLRB,neutral
254618.0,"Cellectar Biosciences Reports Top-Line Response Rate Of 30% From R/R Multiple Myeloma Cohort In Ongoing Phase 2 Study Of CLR 131: 1 Patient Achieved Very Good PArtial Response, All Patients Showed At Least Stable Disease",2019-02-25 08:38:00-05:00,CLRB,positive
254619.0,Cellectar Reports Median Overall Survival Rate In Cohorts 1-4 Of Phase 1 Trial Of CLR131 In Multiple Myeloma; Median Overall Survival Of 22 Months Observed,2019-01-07 08:47:00-05:00,CLRB,neutral
254620.0,Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma,2019-01-07 08:35:00-05:00,CLRB,neutral
254621.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,CLRB,neutral
254622.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018",2018-12-20 11:33:00-05:00,CLRB,negative
254623.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018",2018-12-19 12:43:00-05:00,CLRB,negative
254624.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,CLRB,positive
254625.0,"Cellectar Biosciences shares are trading higher after the company was granted a Japanese patent for CLR 131 in breast, brain and other cancers including leukemia.",2018-12-11 09:30:00-05:00,CLRB,positive
254626.0,"Cellectar Granted Japanese Patent For CLR 131  In Breast, Brain And Other Cancers Including Leukemia",2018-12-11 08:33:00-05:00,CLRB,positive
254627.0,Cellectar Initiates Cohort 6 Of Phase 1b Trial Evaluating CLR 131 In Relapsed/Refractory Multiple Myeloma,2018-12-04 08:32:00-05:00,CLRB,neutral
254628.0,"Stocks Which Set New 52-Week Low The Last Trading Session, Wed., Nov. 21, 2018",2018-11-23 09:09:00-05:00,CLRB,negative
254629.0,Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies,2018-11-12 08:32:00-05:00,CLRB,positive
254630.0,46 Biggest Movers From Friday,2018-10-08 04:46:00-04:00,CLRB,neutral
254631.0,5 Stocks Moving In Thursday's After-Hours Session,2018-10-04 17:25:00-04:00,CLRB,neutral
254632.0,55 Biggest Movers From Yesterday,2018-10-04 05:29:00-04:00,CLRB,neutral
254633.0,43 Stocks Moving In Wednesday's Mid-Day Session,2018-10-03 13:09:00-04:00,CLRB,neutral
254634.0,45 Biggest Movers From Yesterday,2018-10-03 05:40:00-04:00,CLRB,neutral
254635.0,Mid-Morning Market Update: Markets Mostly Higher; PepsiCo Tops Q3 Estimates,2018-10-02 11:06:00-04:00,CLRB,positive
254636.0,UPDATE: Cellectar Results For CLR 131 Show Overall Survival At 19.4 Months,2018-10-02 08:03:00-04:00,CLRB,neutral
254637.0,Cellectar Biosciences Offered Updates On Interim Overall Survival Data From Ongoing Phase 1b Trial Evaluating CLR 131 For Treatment Of Relapsed/Refractory Multiple Myeloma,2018-10-02 08:03:00-04:00,CLRB,neutral
254638.0,51 Biggest Movers From Yesterday,2018-09-28 05:15:00-04:00,CLRB,neutral
254639.0,36 Stocks Moving In Thursday's Mid-Day Session,2018-09-27 12:37:00-04:00,CLRB,neutral
254640.0,41 Biggest Movers From Yesterday,2018-09-27 05:01:00-04:00,CLRB,neutral
254641.0,Cellectar Biosciences shares are up 9.5% to $2.95; Shares continue to move higher after the company on Tuesday received FDA Orphan Drug Designation for its CLR 131 pediatric osteosarcoma treatment.,2018-09-26 12:58:00-04:00,CLRB,positive
254642.0,"The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial",2018-09-26 08:25:00-04:00,CLRB,positive
254643.0,Cellectar's CLR 131 Receives FDA Orphan Drug Designation For Treatment Of Pediatric Osteosarcoma,2018-09-25 08:30:00-04:00,CLRB,neutral
254644.0,Cellectar Biosciences Announces the FDA Has Initiated Talks with the Company to Potentially Exempt it From an Import Alert,2018-09-24 08:05:00-04:00,CLRB,positive
254645.0,56 Biggest Movers From Yesterday,2018-09-21 04:48:00-04:00,CLRB,neutral
254646.0,"Stocks Which Set New 52-Week Low Yesterday, September 17th",2018-09-18 09:27:00-04:00,CLRB,negative
254647.0,"Stocks Which Set New 52-Week Low Friday, September 14",2018-09-17 09:30:00-04:00,CLRB,negative
254648.0,"Cellectar Biosciences shares are up 18.7% after the FDA granted Rare Pediatric Disease designation to the company's CLR 131 for the treatment of osteosarcoma, a form of pediatric cancer.",2018-09-17 08:48:00-04:00,CLRB,negative
254649.0,Cellectar Biosciences' CLR 131 Granted Rare Pediatric Disease Designation,2018-09-17 08:32:00-04:00,CLRB,positive
254650.0,"Stocks Which Set New 52-Week Low Yesterday, September 11th",2018-09-12 15:29:00-04:00,CLRB,negative
254651.0,"The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet",2018-09-11 08:25:00-04:00,CLRB,negative
254652.0,"Stocks Which Set New 52-Week Low Friday, September 7th",2018-09-10 16:38:00-04:00,CLRB,negative
254653.0,Cellectar Biosciences Announces 'Positive' Results from Cohort 5 of Phase 1b Trial,2018-08-20 08:40:00-04:00,CLRB,neutral
254654.0,"Benzinga Pro's Top 10 Most-Searched Tickers Monday, August 13th",2018-08-13 15:46:00-04:00,CLRB,positive
254655.0,44 Stocks Moving In Monday's Mid-Day Session,2018-08-13 12:36:00-04:00,CLRB,neutral
254656.0,Benzinga Pro's 5 Stocks To Watch Today,2018-08-13 09:25:00-04:00,CLRB,neutral
254657.0,Cellectar's CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing's Sarcoma,2018-08-13 08:01:00-04:00,CLRB,neutral
254658.0,"Stocks Which Set New 52-Week Low Yesterday, August 9th",2018-08-10 10:05:00-04:00,CLRB,negative
254659.0,Cellectar Biosciences Q2 EPS $(1.69) Beats $(2.10) Estimate,2018-08-10 08:03:00-04:00,CLRB,neutral
254660.0,"Stocks Which Set New 52-Week Low Yesterday, August 8th",2018-08-09 11:10:00-04:00,CLRB,negative
254661.0,"Stocks Which Set New 52-Week Low Yesterday, August 1st",2018-08-02 11:07:00-04:00,CLRB,negative
254662.0,Cellectar Biosciences Up 12% After Announcement Co. Will Partner With Orano Med To Create Novel Phospholipid Drug Conjugates For Oncologic Therapy,2018-08-01 08:37:00-04:00,CLRB,positive
254663.0,"Stocks Which Set New 52-Week Low Friday, July 27",2018-07-30 12:17:00-04:00,CLRB,negative
254664.0,62 Biggest Movers From Friday,2018-07-30 04:16:00-04:00,CLRB,neutral
254665.0,"Benzinga's Biggest Movers For The Week Of July 23, 2018",2018-07-27 16:00:00-04:00,CLRB,neutral
254666.0,Mid-Afternoon Market Update: NASDAQ Down 1.7%; World Fuel Services Shares Gain Following Upbeat Q2 Results,2018-07-27 14:31:00-04:00,CLRB,positive
254667.0,55 Stocks Moving In Friday's Mid-Day Session,2018-07-27 12:37:00-04:00,CLRB,neutral
254668.0,Mid-Day Market Update: Essendant Rises After Q2 Results; Tonix Pharmaceuticals Shares Plunge,2018-07-27 12:01:00-04:00,CLRB,positive
254669.0,"Stocks Which Set New 52-Week Low Yesterday, July 26th:",2018-07-27 10:54:00-04:00,CLRB,negative
254670.0,Mid-Morning Market Update: Markets Mostly Lower; Twitter Shares Fall Following Q2 Results,2018-07-27 10:21:00-04:00,CLRB,neutral
254671.0,"Benzinga's Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgen's Beat-And-Raise Quarter",2018-07-27 08:44:00-04:00,CLRB,neutral
254672.0,UPDATE: Cellectar Biosciences Prices Offering At $4/Share,2018-07-27 08:40:00-04:00,CLRB,neutral
254673.0,Cellectar Biosciences Prices Public Offering For Gross Proceeds Of $14.4M,2018-07-27 08:36:00-04:00,CLRB,negative
254674.0,36 Stocks Moving In Friday's Pre-Market Session,2018-07-27 08:08:00-04:00,CLRB,neutral
254675.0,10 Stocks Moving In Thursday's After-Hours Session,2018-07-26 16:58:00-04:00,CLRB,neutral
254676.0,"Cellectar Resumes Trade, Now Up 4.87% At $6.25/Share",2018-07-26 09:38:00-04:00,CLRB,neutral
254677.0,"BZ NOTE On Cellectar Price Action: Reminder This Has Been A Recent Low-Float Play, Has ~1.7M Shares In Float",2018-07-26 09:33:00-04:00,CLRB,positive
254678.0,"Cellectar Biosciences Shares Halted On Circuit Breaker Up 20%; Light Volume Of ~11K Shares, Not Seeing News To Justify Spike Higher",2018-07-26 09:32:00-04:00,CLRB,positive
254679.0,41 Biggest Movers From Friday,2018-07-23 04:04:00-04:00,CLRB,neutral
254680.0,31 Stocks Moving In Friday's Mid-Day Session,2018-07-20 12:51:00-04:00,CLRB,neutral
254681.0,50 Biggest Movers From Yesterday,2018-07-20 05:28:00-04:00,CLRB,neutral
254682.0,40 Stocks Moving In Thursday's Mid-Day Session,2018-07-19 13:14:00-04:00,CLRB,neutral
254683.0,51 Biggest Movers From Yesterday,2018-07-19 04:27:00-04:00,CLRB,neutral
254684.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Wed., Jul. 18, 2018",2018-07-18 15:46:00-04:00,CLRB,positive
254685.0,42 Stocks Moving In Wednesday's Mid-Day Session,2018-07-18 12:45:00-04:00,CLRB,neutral
254686.0,"Cellectar Biosciences Shares Up 7.1% Premarket After Co. Announced Encouraging Results From CLR 131 Phase 2 Clinical Trial With Diffuse Large B-Cell Lymphoma Patients, Overall Response Rate Was 33% With Tumor Reductions Ranging From 60% To Over 90%",2018-07-18 09:17:00-04:00,CLRB,positive
254687.0,UPDATE: Cellectar Expands Cohort For CLR 131 To Added 30 Patients,2018-07-18 08:02:00-04:00,CLRB,positive
254688.0,"Cellectar Biosciences Reports Phase 2 Interim Data From CLR 131 In Relapsed/Refractory DLBCL Patients: Showed 33% Overall Response Rate, 50% Clinical Benefit Response",2018-07-18 08:02:00-04:00,CLRB,positive
254689.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Tues., Jul. 17, 2018",2018-07-17 15:27:00-04:00,CLRB,positive
254690.0,28 Stocks Moving In Tuesday's Mid-Day Session,2018-07-17 12:32:00-04:00,CLRB,neutral
254691.0,Mid-Day Market Update: Avid Bioservices Surges Following Earnings Beat; Netflix Shares Plunge,2018-07-17 12:28:00-04:00,CLRB,positive
254692.0,Cellectar Shares Climb After Strong Trial Response For Rare Blood Cancer Drug,2018-07-17 12:04:00-04:00,CLRB,neutral
254693.0,Mid-Morning Market Update: Markets Open Lower; Goldman Sachs Earnings Top Expectations,2018-07-17 10:25:00-04:00,CLRB,negative
254694.0,Cellectar Reports 94% Reduction in Overall Tumor Volume in Waldenstrom Macroglobulinemia Patient in Phase 2 CLR 131 Clinical Study,2018-07-17 08:02:00-04:00,CLRB,negative
254695.0,"A Peek Into The Markets: US Stock Futures Edge Higher, Bank of America Profit Tops Views",2018-07-16 07:07:00-04:00,CLRB,positive
254696.0,"6 Stocks To Watch For July 16, 2018",2018-07-16 04:33:00-04:00,CLRB,neutral
254697.0,Cellectar Announces 1-for-10 Reverse Stock Split,2018-07-13 16:05:00-04:00,CLRB,neutral
254698.0,30 Biggest Movers From Yesterday,2018-07-10 05:02:00-04:00,CLRB,neutral
254699.0,28 Stocks Moving In Monday's Mid-Day Session,2018-07-09 12:16:00-04:00,CLRB,neutral
254700.0,Cellectar's CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing's Sarcoma,2018-07-09 08:06:00-04:00,CLRB,neutral
254701.0,"Benzinga's Daily Biotech Pulse: Titan's Parkinson's Disease Drug Implant Trial, Juniper Pharma Sells Itself At 32% Premium",2018-07-03 07:51:00-04:00,CLRB,neutral
254702.0,Cellectar Announces Expansion of Diffuse Large B-Cell Lymphoma Cohort in CLR 131 Phase 2 Trial,2018-06-28 08:07:00-04:00,CLRB,neutral
254703.0,"Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading",2018-06-27 08:14:00-04:00,CLRB,negative
254704.0,"Benzinga's Daily Biotech Pulse: Epidiolex, Roche's Influenza Drug Gets Priority Review Status, Xeris Jumps On Positive Trial Results",2018-06-26 08:34:00-04:00,CLRB,positive
254705.0,"Benzinga's Daily Biotech Pulse: FDA Greenlights Tandem Diabetes' Insulin Pump, More IPOs On Tap",2018-06-22 08:51:00-04:00,CLRB,neutral
254706.0,"Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street",2018-06-21 08:39:00-04:00,CLRB,neutral
254707.0,Cellectar Granted U.S. Patent For Treatment Of Various Cancers And Cancer Stem Cells With CLR 131,2018-06-07 08:34:00-04:00,CLRB,negative
254708.0,40 Biggest Movers From Yesterday,2018-06-07 04:50:00-04:00,CLRB,neutral
254709.0,28 Stocks Moving In Wednesday's Mid-Day Session,2018-06-06 12:24:00-04:00,CLRB,neutral
254710.0,Mid-Morning Market Update: Markets Mostly Higher; Signet Jewelers Earnings Top Estimates,2018-06-06 10:16:00-04:00,CLRB,positive
254711.0,Cellectar Biosciences Shares Up 43.5% Premarket After FDA Granted Rare Pediatric Disease Designation To Co.'s CLR 131 For Rhabdomyosarcoma,2018-06-06 09:11:00-04:00,CLRB,positive
254712.0,FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences' CLR 131 for the Treatment of Rhabdomyosarcoma,2018-06-06 08:03:00-04:00,CLRB,positive
254713.0,"Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended",2018-05-25 09:19:00-04:00,CLRB,negative
254714.0,"Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings",2018-05-24 08:37:00-04:00,CLRB,neutral
254715.0,"Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing",2018-05-23 08:15:00-04:00,CLRB,neutral
254716.0,Cellectar Biosciences Q1 EPS $(0.21) Misses $(0.20) Estimate,2018-05-11 08:02:00-04:00,CLRB,negative
254717.0,Cellectar Biosciences Granted FDA Orphan Drug Designation For CLR 131,2018-05-09 14:28:00-04:00,CLRB,positive
254718.0,Cellectar Biosciences Reports Received Rare Pediatric Disease Designation For CLR 131 To Treat Neuroblastoma,2018-05-02 08:13:00-04:00,CLRB,positive
254719.0,Cellectar Biosciences Names Brian Posner CFO,2018-04-04 08:04:00-04:00,CLRB,neutral
254720.0,Cellectar Reports Issuance of U.S. Patent Covering CLR 131 Use in Multiple Myeloma,2018-04-03 08:04:00-04:00,CLRB,neutral
254721.0,Cellectar Granted A US Patent for Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles,2018-03-27 08:10:00-04:00,CLRB,positive
254722.0,Cellectar Biosciences Reorts FY17 EPS $(1.07) Misses $(0.96) Est.,2018-03-21 16:14:00-04:00,CLRB,negative
254723.0,"Earnings Scheduled For March 21, 2018",2018-03-21 05:20:00-04:00,CLRB,neutral
254724.0,"Cellectar Biosciences Shares Up 2.5% For Session, Down 22% From Pre-Market Highs; FDA Late Fri. Granted CLR 131 Orphan Drug Status For Neuroblastoma",2018-03-19 11:29:00-04:00,CLRB,positive
254725.0,Benzinga Pro's 5 Stocks To Watch Today,2018-03-19 08:45:00-04:00,CLRB,neutral
254726.0,Cellectar Biosciences Granted Orphan Drug Designation for CLR 131 to Treat Neuroblastoma,2018-03-19 08:22:00-04:00,CLRB,positive
254727.0,FDA.gov Site Shows Cellectar Biosciences With Orphan Drug Desingation For Neuroblastoma Treatment,2018-03-16 16:12:00-04:00,CLRB,neutral
254728.0,Cellectar Receives USPTO Notice of Allowance for Patent Covering Use of CLR 131 in Multiple Myeloma,2018-02-07 08:15:00-05:00,CLRB,neutral
254729.0,Cellectar Starts DLBCL Cohort in Phase 2 Trial of CLR 131 in Refractory B-Cell Hematologic Cancers,2018-01-29 08:01:00-05:00,CLRB,neutral
254730.0,Cellectar Biosciences Reports Filing Of IND For Phase 1 Trial Of CLR 131 In Pediatric Cancers,2017-12-14 08:45:00-05:00,CLRB,neutral
254731.0,Cellectar Announces Expansion To 40 Patients of Relapsed/Refractory Multiple Myeloma Cohort in Phase 2 Trial of CLR 131,2017-12-06 08:05:00-05:00,CLRB,neutral
254732.0,Cellectar Biosciences Reports Q3 EPS $(0.26) vs $(0.25) Est.,2017-11-09 16:23:00-05:00,CLRB,neutral
254733.0,Cellectar Biosciences Reports Introduction Of Multi-Dose Regimen In 5th Cohort Of Phase 1 Trial OF CLR 131 In Multiple Myeloma,2017-10-24 08:35:00-04:00,CLRB,neutral
254734.0,Cellectar Biosciences Receives Japanese Patents for CLR 131 and CLR 125,2017-10-17 08:37:00-04:00,CLRB,neutral
254735.0,CORRECTION: Cellectar Biosciences Reports $7.76M Registered Direct ATM Offering,2017-10-10 13:35:00-04:00,CLRB,neutral
254736.0,Cellectar Biosciences Reports $7.76M Registered Direct ATM Offering,2017-10-10 13:31:00-04:00,CLRB,neutral
254737.0,Cellectar Biosciences Reports Extended Collaboration Deal With Pierre Fabre For Development Of New Phospholipid Drug Conjugates,2017-10-10 07:36:00-04:00,CLRB,neutral
254738.0,Cellectar Reports Strategic Collab. With Onconova Therapeutics Related To Developing Of New Phospholipid Drug Conjugates,2017-09-21 08:38:00-04:00,CLRB,neutral
254739.0,Cellectar Biosciences Reports PDC Platform 'has generated numerous PDC molecules that show significant improved pharmacologic activity versus the payload molecule alone',2017-08-22 08:33:00-04:00,CLRB,positive
254740.0,Cellectar Biosciences Reports Q2 EPS $(0.23) vs. $(0.24) Est.,2017-08-14 16:52:00-04:00,CLRB,neutral
254741.0,Cellectar Biosciences Reports CLR 131 Achieved Overall Survival Of 22+ Months In Advanced Multiple Myeloma Patients,2017-08-08 08:38:00-04:00,CLRB,positive
254742.0,Cellectar Biosciences Signs Partnership with Avicenna Oncology to Develop New PDCs for Solid Tumors,2017-08-01 08:34:00-04:00,CLRB,positive
254743.0,S-3 from Cellectar Biosciences Shows Registration for $50M Mixed Securities Shelf Offering,2017-06-05 17:17:00-04:00,CLRB,positive
254744.0,"Cellectar Biosciences Offers 3 Abstracts on Dosing Regimens of CLR 131, Discusses Study Setup",2017-05-18 08:37:00-04:00,CLRB,neutral
254745.0,Cellectar Biosciences Reports Q1 EPS $(0.24) vs $(0.23) Est.,2017-05-11 16:25:00-04:00,CLRB,neutral
254746.0,Cellectar Biosciences Reports Received Added US Patents for PDC Optical Agents in Detection of Multiple Cancers,2017-04-25 08:35:00-04:00,CLRB,neutral
254747.0,"Cellectar Biosciences Receives Japanese Patent for CLR 131, CLR 125 For Cancer Stem Cell Treatment",2017-04-18 08:33:00-04:00,CLRB,negative
254748.0,Cellectar Biosciences Names John Friend Chief Medical Officer,2017-04-12 08:31:00-04:00,CLRB,positive
254749.0,Cellectar Biosciences Reports Initiation of Phase II Study of CLR 131,2017-03-30 08:33:00-04:00,CLRB,neutral
254750.0,Cellectar Biosciences Reports Patent Grant for PET Imaging PDC,2017-03-21 08:34:00-04:00,CLRB,positive
254751.0,Cellectar Reports FY16 EPS $(1.36) vs $(0.54) Est.,2017-03-15 16:20:00-04:00,CLRB,neutral
254752.0,15 Biggest Mid-Day Gainers For Monday,2017-02-27 12:48:00-05:00,CLRB,neutral
254753.0,Mid-Day Market Update: Gogo Surges After Strong Q4 Results; AmTrust Financial Shares Slide,2017-02-27 12:07:00-05:00,CLRB,positive
254754.0,Mid-Morning Market Update: Markets Edge Lower; Sotheby's Beats Q4 Views,2017-02-27 10:04:00-05:00,CLRB,negative
254755.0,Cellectar Biosciences Falls to Low of $1.99 on Volume,2017-02-23 13:00:00-05:00,CLRB,negative
254756.0,Cellectar Biosciences Begins Fourth Cohort of Its Phase I Clinical Trial of CLR 131 in Multiple Myeloma,2017-02-22 08:30:00-05:00,CLRB,neutral
254757.0,20 Biggest Mid-Day Gainers For Tuesday,2017-01-24 12:39:00-05:00,CLRB,neutral
254758.0,Mid-Morning Market Update: Markets Open Higher; Verizon Earnings Miss Expectations,2017-01-24 09:50:00-05:00,CLRB,negative
254759.0,Cellectar Biosciences Reports Additional US Patent Granted for CLR 131 and CLR 125 in a Broad Range of Solid Tumors,2017-01-24 08:30:00-05:00,CLRB,positive
254760.0,"Ladenburg Thalmann Initiates Coverage On Cellectar Biosciences at Buy, Announces $2.70 Target",2016-12-21 06:33:00-05:00,CLRB,neutral
254761.0,Cellectar Biosciences Announces US and Japanese Patent Allowances for Diagnostic and Optical Imaging PDCs,2016-12-20 08:37:00-05:00,CLRB,neutral
254762.0,Cellectar Biosciences Reports USPTO Grants Patent Allowances for Radiotherapeutic PDCs for A Variety of Solid Tumor Types,2016-12-14 08:31:00-05:00,CLRB,neutral
254763.0,Cellectar Biosciences Announces USPTO Grants Patent for Paclitaxel PDC; Provides Additional Patent Protection for Select Solid Tumors Through 2035,2016-12-12 08:33:00-05:00,CLRB,positive
254764.0,"Cellectar Biosciences Announces Partnership with Radiopharmaceutical Specialists, CPDC, to Establish Manufacturing Capacity in Anticipation of CLR 131 Pivotal Trial and Commercial Production",2016-11-28 08:05:00-05:00,CLRB,positive
254765.0,Mid-Afternoon Market Update: Caleres Rises On Earnings Beat; Juno Therapeutics Shares Slide,2016-11-23 14:24:00-05:00,CLRB,positive
254766.0,A Tough Day For Some Biotech Bulls,2016-11-23 13:45:00-05:00,CLRB,negative
254767.0,18 Biggest Mid-Day Losers For Wednesday,2016-11-23 13:06:00-05:00,CLRB,negative
254768.0,Mid-Day Market Update: Eli Lilly Tumbles After Alzheimer's Study Fails To Meet Goals; Euroseas Shares Rise,2016-11-23 12:05:00-05:00,CLRB,negative
254769.0,Mid-Morning Market Update: Markets Mostly Lower; Deere Tops Q4 Views,2016-11-23 10:08:00-05:00,CLRB,positive
254770.0,"Cellectar Biosciences Announces Pricing of $8,000,000 Public Offering",2016-11-23 08:30:00-05:00,CLRB,neutral
254771.0,Cellectar Biosciences Spiked 30% On Phase 2 INC Contract,2016-11-15 13:28:00-05:00,CLRB,neutral
254772.0,15 Biggest Mid-Day Gainers For Tuesday,2016-11-15 12:35:00-05:00,CLRB,neutral
254773.0,"Cellectar Biosciences Announces INC Research as the CRO for the Phase II Trial of CLR 131 in Hematologic Malignancies; $2M NCI Grant Covers Half of Study Cost, with Potential Option to Pursue Additional $3M for Pivotal Trial",2016-11-15 10:05:00-05:00,CLRB,positive
254774.0,"Earnings Scheduled For November 11, 2016",2016-11-11 04:11:00-05:00,CLRB,neutral
254775.0,UPDATE: Cellectar Sees Prelim. Data on CLR 131 as Early as 2H'17,2016-10-31 09:46:00-04:00,CLRB,neutral
254776.0,"Cellectar Biosciences Reports Design for NCI-Supported Phase II Study of CLR 131 in Multiple Myeloma, Other Hematologic Malignancies; Co. Accelerates Guidance for Initiation of Trial",2016-10-31 09:46:00-04:00,CLRB,neutral
254777.0,Cellectar Biosciences Announces Enrollment of First Patient into Third Cohort of Its Phase I Clinical Study of CLR 131 in Multiple Myeloma,2016-10-06 08:30:00-04:00,CLRB,neutral
254778.0,Cellectar Biosciences Announces USPTO Issues Formal Patent Allowance for CLR 1603,2016-10-04 08:31:00-04:00,CLRB,neutral
254779.0,Cellectar Biosciences Reports New Positive Data from Phase I Clinical Study of CLR 131 in Multiple Myeloma,2016-09-29 08:31:00-04:00,CLRB,positive
254780.0,Cellectar Biosciences Announces Lead Compound CLR 131 To Be Studied In Head and Neck Cancer in $12M University of Wisconsin SPORE Grant,2016-09-12 08:33:00-04:00,CLRB,negative
254781.0,"Cellectar Biosciences Reports Q2 R&D Expenses $1M, Cash, Cash Equivalents of $7.9M at End of Qtr.",2016-08-11 16:46:00-04:00,CLRB,neutral
254782.0,Mid-Morning Market Update: Markets Open Higher; BlackBerry Profit Tops Views,2016-06-23 10:12:00-04:00,CLRB,positive
254783.0,Cellectar Biosciences Reports Results of NCI-Sponsored Study of CLR 125 Showing Potential Effect Against Triple Negative Breast Cancer,2016-06-23 08:32:00-04:00,CLRB,negative
254784.0,10 Biggest Mid-Day Gainers For Wednesday,2016-06-15 12:31:00-04:00,CLRB,neutral
254785.0,Mid-Day Market Update: Patriot National Climbs Following Offer from Ebix; Carbylan Therapeutics Shares Tumble,2016-06-15 12:14:00-04:00,CLRB,positive
254786.0,Mid-Morning Market Update: Markets Open Higher; Aegerion Pharmaceuticals And QLT Agree To Merge,2016-06-15 09:55:00-04:00,CLRB,positive
254787.0,"Cellectar Biosciences Reports Results of In Vivo Study Demonstrating PDC Platform Delivery of Paclitaxel to be Superior in Tumor Targeting to Free Paclitaxel, Says CLR 1602 Tumor Selectivity ~30 Times Greater Than Paclitaxel Alone",2016-06-15 08:31:00-04:00,CLRB,positive
254788.0,Richard Hertzberg Reports 6.638% Stake in  Cellectar Biosciences in 13G,2016-06-02 14:05:00-04:00,CLRB,neutral
254789.0,Cellectar Biosciences Announces USPTO Issues Patent for its Radiotherapeutic PDC Portfolio,2016-05-31 08:31:00-04:00,CLRB,neutral
254790.0,Mid-Morning Market Update: Markets Open Higher; Express Earnings Miss Views,2016-05-25 09:50:00-04:00,CLRB,negative
254791.0,Cellectar Biosciences Issues U.S. Patent for New PDC with Paclitaxel. Covers CLR 1603,2016-05-25 08:34:00-04:00,CLRB,neutral
254792.0,Top 4 Pre-Market Losers,2016-05-24 09:46:00-04:00,CLRB,negative
254793.0,Mid-Afternoon Market Update: New York & Company Falls On Weak Results; InterOil Shares Spike Higher,2016-05-20 14:44:00-04:00,CLRB,negative
254794.0,Flavor Of The Day: Cellectar Biosciences,2016-05-20 14:37:00-04:00,CLRB,neutral
254795.0,Cellectar Biosciences Jumps 200% After Getting Patent Identification Numbers For Cancer-Targeting Drug Vehicles,2016-05-20 13:09:00-04:00,CLRB,neutral
254796.0,10 Biggest Mid-Day Gainers For Friday,2016-05-20 12:35:00-04:00,CLRB,neutral
254797.0,Cellectar Reports Patent App for Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles Published by USPTO,2016-05-20 08:31:00-04:00,CLRB,negative
254798.0,Cellectar Biosciences Closes $8 Million Public Issue,2016-04-20 12:31:00-04:00,CLRB,neutral
254799.0,Collectar Biosciences Prices $7.0 Million Public Issue,2016-04-15 10:44:00-04:00,CLRB,neutral
254800.0,Stocks Hitting 52-Week Lows,2016-04-15 10:15:00-04:00,CLRB,negative
254801.0,Mid-Morning Market Update: Markets Edge Lower; Citigroup Profit Tops Views,2016-04-15 10:07:00-04:00,CLRB,positive
254802.0,Cellectar Biosciences Prices Offer at $2.13/Share for Gross Proceeds ~$7M,2016-04-15 08:31:00-04:00,CLRB,negative
254803.0,Stocks Hitting 52-Week Lows,2016-03-30 10:25:00-04:00,CLRB,negative
254804.0,Cellectar Biosciences Reports FY15 EPS $(7.03) vs. Prior Year Quarter $(17.53),2016-03-10 16:23:00-05:00,CLRB,neutral
254805.0,Cellectar Biosciences Reports 1-for-10 Reverse Stock Split,2016-03-04 16:15:00-05:00,CLRB,neutral
254806.0,"Cellectar Biosciences Says Safety, Activity Data from Phase 1 Trial of CLR 131 in Multiple Myeloma Reviewed, Performance Triggered Advancement Into Second Cohort at Higher Dose",2016-01-05 08:33:00-05:00,CLRB,positive
254807.0,Cellectar Biosciences to Give Update on Phase 1 Multiple Myeloma Study In January 2016,2015-12-09 08:31:00-05:00,CLRB,neutral
254808.0,S-3 from Cellectar Biosciences Shows Registration for 1.5M Shares Common Stock Offering via Selling Holders,2015-11-24 16:22:00-05:00,CLRB,positive
254809.0,"Cellectar Biosciences Reports Q3 EPS $(0.25), no estimates",2015-11-12 17:05:00-05:00,CLRB,negative
254810.0,Cellectar Biosciences Provides Phospholipid Drug Conjugate (PDC) Platform Development Update,2015-11-02 08:33:00-05:00,CLRB,neutral
254811.0,Cellectar Biosciences Closes on $3.3M Financing,2015-10-02 08:31:00-04:00,CLRB,neutral
254812.0,Cellectar Biosciences Awarded $2.3M National Cancer Institute Fast-Track SBIR Grant to Advance Phospholipid Drug Conjugate (PDC) Delivery Platform,2015-10-01 08:31:00-04:00,CLRB,negative
254813.0,Cellectar Biosciences Introduces Phospholipid Ether-Drug Conjugate (PDC) Platform for Targeted Delivery of Chemotherapeutics,2015-08-21 08:30:00-04:00,CLRB,neutral
254814.0,Morning Market Gainers,2015-06-16 09:39:00-04:00,CLRB,neutral
254815.0,Cellectar Biosciences Reports CLR1502 Development Program to be Classified as Combination Product by FDA,2015-06-11 16:16:00-04:00,CLRB,neutral
254816.0,"Cellectar Bioscience Reports Q1 Loss $0.30, no estimates",2015-05-21 16:16:00-04:00,CLRB,negative
254818.0,"Cellectar Bioscience Reports FY 2014 -$1.77, No Estimates Available",2015-03-24 16:17:00-04:00,CLRB,negative
254819.0,Cellectar Biosciences Granted Orphan Designation For I-131-CLR1404,2014-12-04 16:07:00-05:00,CLRB,positive
254820.0,Cellectar Biosciences Announces Publication of Findings Demonstrating Efficacy of Its Phospholipid Ether Analog Platform in Detecting Colorectal Cancer,2014-10-15 08:33:00-04:00,CLRB,negative
254821.0,Cellectar Announces Acceptance Of Investigational New Drug (IND),2014-09-04 08:36:00-04:00,CLRB,positive
254822.0,Cellectar Biosciences Reports Q2 2014 EPS of $(0.73) Compared To $(0.72) Q2 2013,2014-08-20 16:16:00-04:00,CLRB,neutral
254823.0,Cellectar Biosciences Announces Closing Of Public Offering And Partial Exercise Of Underwriter's Over-Allotment Option,2014-08-20 16:07:00-04:00,CLRB,neutral
